| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 5.2 | 5.2 |
| Gross profit | 2.8 | 2.6 |
| Net income | 0.4 | 0.4 |
| EPS (diluted, $ a share) | $0.02 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -13.5% |
|---|---|
| Revenue, year on year | +1.3% |
| Gross margin | 52.9% |
| Operating margin | 7.3% |
10-Q filed with the SEC, NASDAQ: SOTK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sono Tek Corp: key numbers
- Share price
- $4.14Close, Nov 16
- Market cap
- $65.1M
- Shares outstanding
- 15.75MLatest SEC cover page
- Sector
- Technology
- Industry
- Special Industry Machinery, NECSIC 3559
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sono Tek Corp
All →Sono-Tek Earnings Call: Key Takeaways
Sonotech delivered solid H1 FY2027 results with 6% revenue growth and significant margin expansion, driven by a strategic shift toward high-value medical production systems and record-breaking alternative energy orders.
- Call
- Oct 14, 2026, 10:30 AM ET
Sono Tek Financial Results
Sono-Tek reported fiscal second quarter 2027 results with net sales of $5.23 million and net income of $366,000. For the first half of the fiscal year, revenue increased 6% to $10.89 million, driven by a 289% surge in medical market sales. The company reiterated its full-year guidance for flat to modest revenue growth due to the timing of large orders.
- Term
- Q2 2027
“Fiscal 2027 is progressing well, with solid first-half revenue growth, meaningful gross margin expansion and strong improvement in operating profitability. These results reflect disciplined execution across our operations and continued progress with our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.”
Steve Harshbarger, President and Chief Executive Officer